Wyeth Reports Earnings Results for the 2007 Fourth Quarter and... (ed 3% to $1294 millionfor the 2007 full ...)

Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year

Date:1/31/2008

ed 3% to $1,294 million for the 2007 full year due to lower alliance revenue associated with sales of the CYPHER stent and Altace. The decrease was partially offset by higher sales of Enbrel in the United States and Canada. Excluding the favorable impact of foreign exchange, worldwide Pharmaceuticals net revenue increased 6% for the 2007 fourth quarter and 8% for the 2007 full year.

Consumer Healthcare

Worldwide Consumer Healthcare net revenue increased 10% for the 2007 fourth quarter and 8% for the 2007 full year due primarily to an increase in sales of Advil(R), Advil(R) PM, Advil(R) Cold & Sinus, Centrum(R), Caltrate(R) and Chapstick(R), partially offset by lower sales of Dimetapp(R) and Robitussin(R) primarily due to the voluntary recall and replacement program initiated during the 2007 third quarter in connection with the redesign of dosing cups. Excluding the favorable impact of foreign exchange, worldwide

Consumer Healthcare net revenue increased 5% for the 2007 fourth quarter and full year.

Animal Health

Worldwide Animal Health net revenue increased 24% for the 2007 fourth quarter and 11% for the 2007 full year primarily due to higher sales of companion animal products, which included sales of our recently launched ProMeris(R) flea and tick products, as well as higher sales of livestock, equine and poultry products. Excluding the favorable impact of foreign exchange, worldwide Animal Health net revenue increased 17% for the 2007 fourth quarter and 7% for the 2007 full year.

2008 Earnings Guidance

The Company estimates pro forma diluted earnings per share for 2008 will be $3.35 to $3.49, a decrease of 1% to 5% versus 2007. This estimate reflects the impact of generic Protonix and certain assumptions about generic competition for Zosyn and Effexor. The 2008 estimate is considered pro forma as it excludes potential charges resulting from the Company's ongoing productivity initiatives. Net revenue in 2008 is expec
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

Post Your Comments:

Wyeth Reports Earnings Results for the 2007 Fourth Quarter and...(ed 3% to $1294 millionfor the 2007 full ...)